UY28126A1 - Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular - Google Patents

Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular

Info

Publication number
UY28126A1
UY28126A1 UY28126A UY28126A UY28126A1 UY 28126 A1 UY28126 A1 UY 28126A1 UY 28126 A UY28126 A UY 28126A UY 28126 A UY28126 A UY 28126A UY 28126 A1 UY28126 A1 UY 28126A1
Authority
UY
Uruguay
Prior art keywords
eye
treatment
dry eyes
drought
rimexolone
Prior art date
Application number
UY28126A
Other languages
English (en)
Inventor
Ernesto J Castillo
John M Yanni
Daniel A Gamache
Steven T Miller
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of UY28126A1 publication Critical patent/UY28126A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen composiciones oftálmicas tópicas y métodos para el tratamiento de la sequedad ocular. Las composiciones y métodos del invento se basan en el descubrimiento de que las propiedades selectivas para la superficie ocular de la rimexolona glucocorticoide hacen que este agente antiinflamatorio sea especialmente apropiado para el tratamiento de la sequedad ocular. Como resultado de la limitada capacidad de la rimexolona de penetrar la córnea, una alta porción de la droga se mantiene en la superficie del ojo, que es el lugar primario de las afecciones inflamatorias asociadas con la sequedad ocular. Esto permite que se utilice una concentración muy baja de la droga, lo que a su vez reduce la posibilidad de un aumento de la presión intraocular y la formación de cataratas.
UY28126A 2002-12-24 2003-12-15 Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular UY28126A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43625502P 2002-12-24 2002-12-24

Publications (1)

Publication Number Publication Date
UY28126A1 true UY28126A1 (es) 2004-06-30

Family

ID=32682365

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28126A UY28126A1 (es) 2002-12-24 2003-12-15 Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular

Country Status (23)

Country Link
US (3) US20040132704A1 (es)
EP (1) EP1575597B1 (es)
JP (1) JP2006513213A (es)
KR (2) KR100889170B1 (es)
CN (1) CN100388919C (es)
AR (1) AR042790A1 (es)
AT (1) ATE419856T1 (es)
AU (1) AU2003299696B2 (es)
BR (1) BR0317774A (es)
CA (1) CA2507375C (es)
CY (1) CY1108862T1 (es)
DE (1) DE60325770D1 (es)
DK (1) DK1575597T3 (es)
ES (1) ES2316867T3 (es)
MX (1) MXPA05006985A (es)
PL (1) PL378877A1 (es)
PT (1) PT1575597E (es)
RU (1) RU2330668C2 (es)
SI (1) SI1575597T1 (es)
TW (1) TWI335819B (es)
UY (1) UY28126A1 (es)
WO (1) WO2004058273A1 (es)
ZA (1) ZA200503975B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7779039B2 (en) 2004-04-02 2010-08-17 Salesforce.Com, Inc. Custom entities and fields in a multi-tenant database system
CA2580659C (en) 2004-09-15 2013-02-26 Ivx Animal Health, Inc. Corticosteroid having low systemic absorption
CN101258483B (zh) 2005-09-09 2015-08-12 易享信息技术（上海）有限公司 用于在多租户数据库环境中导出、发布、浏览和安装随需应用的系统及其方法
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
US8138156B2 (en) * 2006-10-18 2012-03-20 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
US8629099B2 (en) * 2008-03-25 2014-01-14 Bausch & Lomb Incorporated Ophthalmic compositions comprising a dipeptide
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US20100087550A1 (en) * 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
EP3643312A1 (en) 2009-05-22 2020-04-29 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
PL2437762T3 (pl) * 2009-06-05 2018-01-31 Allergan Inc Sztuczne łzy i ich zastosowania terapeutyczne
AR078012A1 (es) * 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
EP3050882B1 (en) 2010-03-10 2018-01-31 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8664180B2 (en) 2012-02-06 2014-03-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US8324171B1 (en) 2012-02-06 2012-12-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
WO2013126602A1 (en) * 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
CN105189509B (zh) 2013-03-06 2017-12-19 因赛特公司 用于制备jak抑制剂的方法及中间体
SG10201912203XA (en) 2013-08-07 2020-02-27 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
RU2559580C1 (ru) * 2014-03-18 2015-08-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) Препарат для лечения синдрома "сухого глаза"
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CN106420797A (zh) * 2016-12-06 2017-02-22 郑州郑先医药科技有限公司 一种治疗干眼病的西药组合及其制备方法
CN106581035A (zh) * 2016-12-06 2017-04-26 郑州郑先医药科技有限公司 一种治疗干眼病的西药组合物
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3746429B1 (en) 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
PT3773593T (pt) 2018-03-30 2024-06-25 Incyte Corp Tratamento da hidradenite supurativa com inibidores de jak
KR102269835B1 (ko) 2019-10-08 2021-06-29 한국전력공사 펜형 케이블 식별장치 및 케이블 식별 시스템
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US20240166971A1 (en) * 2022-10-26 2024-05-23 Bausch + Lomb Ireland Limited Contact lens treating solution

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63203620A (ja) * 1985-10-30 1988-08-23 アルコン　ラボラトリ−ズ　インコ−ポレイテツド 眼科用の抗炎症性組成物
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US5360611A (en) * 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
WO1993017664A1 (en) * 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
ATE185697T1 (de) * 1992-04-21 1999-11-15 Schepens Eye Res Inst Androgentherapie am auge beim sjögrensyndrom
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
ATE300936T1 (de) * 1992-05-06 2005-08-15 Alcon Lab Inc Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
JPH06153607A (ja) * 1992-11-30 1994-06-03 Kinsaku Kida 農耕用作業車と農耕作業部との連結装置
CA2134376C (en) * 1993-12-20 2001-10-23 Haresh G. Bhagat Combinations of polymers for use in physiological tear compositions
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
RU2126669C1 (ru) * 1997-04-25 1999-02-27 Новокузнецкий государственный институт усовершенствования врачей Способ лечения синдрома сухого глаза
WO1998055126A2 (en) * 1997-06-04 1998-12-10 Akzo Nobel N.V. Use of anti-inflammatory steroids for the treatment of chronic inflammatory intestinal diseases
EP1214056B1 (en) * 1999-09-24 2003-10-29 Alcon Inc. Topical suspension formulations containing ciprofloxacin and dexamethasone

Also Published As

Publication number Publication date
ZA200503975B (en) 2006-12-27
BR0317774A (pt) 2005-11-22
US20080096852A1 (en) 2008-04-24
RU2330668C2 (ru) 2008-08-10
KR20050086937A (ko) 2005-08-30
ATE419856T1 (de) 2009-01-15
MXPA05006985A (es) 2005-08-16
TW200418492A (en) 2004-10-01
DE60325770D1 (de) 2009-02-26
PT1575597E (pt) 2009-02-02
SI1575597T1 (sl) 2009-04-30
CA2507375A1 (en) 2004-07-15
TWI335819B (en) 2011-01-11
PL378877A1 (pl) 2006-05-29
CY1108862T1 (el) 2014-07-02
WO2004058273A1 (en) 2004-07-15
AR042790A1 (es) 2005-07-06
US20060058277A1 (en) 2006-03-16
AU2003299696A1 (en) 2004-07-22
CA2507375C (en) 2009-11-24
ES2316867T3 (es) 2009-04-16
RU2005123388A (ru) 2006-01-20
CN1732008A (zh) 2006-02-08
DK1575597T3 (da) 2009-03-16
HK1076248A1 (en) 2006-01-13
CN100388919C (zh) 2008-05-21
JP2006513213A (ja) 2006-04-20
EP1575597B1 (en) 2009-01-07
AU2003299696B2 (en) 2009-08-13
US20040132704A1 (en) 2004-07-08
KR100889170B1 (ko) 2009-03-16
KR20090018222A (ko) 2009-02-19
EP1575597A1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
UY28126A1 (es) Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular
UY28709A1 (es) Derivados de prostaglandinas
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
DE602006006308D1 (de) Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
AR043356A1 (es) Dispositvo de liberacion sostenida para la administracion ocular de inhibidores de la anhidrasa carbonica y uso de inhibidores de la anhidrasa carbonica para su preparacion
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
BR112022015579A2 (pt) Composições para tratamento de doenças oculares
ZA202300309B (en) Glucocorticoid-sparing agent
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
AR051472A1 (es) Uso de inhibidores de las quinasas jun n- terminales para eltratamiento de la retinopatia glaucomatosa y enfermedades oculares
CA3167959A1 (en) Prodrug for the treatment of disease and injury of oxidative stress
UY28202A1 (es) Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares.
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
MX2007010295A (es) Composiciones oftalmologicas novedosas y metodo para su uso.
AR030345A1 (es) Metodo de tratamiento de desordenes relacionados con angiogenesis
AR033207A1 (es) Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
UY29627A1 (es) Derivados de prostaglandina
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150519